• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Organigram Announces Appointment of Chief Executive Officer

    11/25/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGI alert in real time by email

    Organigram Global Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company's new Chief Executive Officer (CEO). Mr. Yamanaka is expected to assume the role effective on or about January 15, 2026. Mr. Yamanaka will also join the Company's board of directors when he assumes the role of Chief Executive Officer.

    Mr. Yamanaka is a seasoned executive, having spent more than 20 years at British American Tobacco, with extensive experience in strategy and general management across Europe and Asia. His career is distinguished by a strong track record of creating value-driven strategies, transforming businesses, and delivering outstanding commercial results.

    As Global Head of Strategy at BAT, Mr. Yamanaka was instrumental in developing the Group strategy. Prior to his role as Global Head of Strategy, he served as Area Director for North Asia (Japan and South Korea), where he achieved record market share in Japan. Before his role in Asia, Mr. Yamanaka successfully transformed BAT's Northern Europe Area from a traditional business into one positioned for rapid sustainable growth through the acquisition of a nicotine pouch business that has become the largest growth category for the BAT group.

    Peter Amirault, current Board chairman, has been appointed by the Board to serve as executive chair on an interim basis effective December 1st, to oversee day-to-day management of the Company until Mr. Yamanaka fully assumes the CEO role. During this period, Geoff Machum, chair of the Board's Governance, Nominating and Sustainability Committee, will serve as the independent lead director. "We are excited to have James join the Organigram team," said Mr. Amirault. "James' history of driving strong international growth aligns perfectly with Organigram's global aspirations. His experience in building high-performing teams and delivering results will be invaluable as we expand our international presence."

    "I am thrilled to take on this new challenge," said Mr. Yamanaka. "I have watched Organigram evolve into Canada's number one recreational cannabis company by market share and believe it is well positioned to become a global leader in the cannabis industry. I look forward to building an international presence on Organigram's strong foundation of high-quality products, trusted brands, and a commitment to industry-leading innovation."

    Mr. Yamanaka holds a BA in Political Science and Economics from UC San Diego, an M.S. in Foreign Service from Georgetown University, and an MBA from London Business School. He will be based in Toronto, Ontario. He will assume the role as CEO of Organigram following completion of required procedures including customary immigration matters.

    Forward-Looking Information

    This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include consumer demand and preferences, future prospects and factors and risks disclosed in the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR Next (see www.sec.gov).

    Examples of forward-looking statements in this news release include, among others, statements regarding Mr. Yamanaka's effective start date as CEO, satisfactory completion of required immigration and security clearance procedures and consequential interim appointments of executive chair and lead director positions. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all.

    The forward-looking information included in this news release is made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251125699142/en/

    For Media Enquiries

    Megan McCrae – Senior Vice President, Corporate Strategy and International Growth

    [email protected]

    Get the next $OGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGI

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    4/15/2024Neutral → Buy
    Alliance Global Partners
    1/13/2023Hold → Buy
    Stifel
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    12/8/2021$5.50 → $5.70Overweight
    Cantor Fitzgerald
    More analyst ratings

    $OGI
    SEC Filings

    View All

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    12/5/25 12:59:47 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    12/4/25 2:58:46 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    11/25/25 2:25:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organigram to Report Fourth Quarter Fiscal 2025 Results on December 16, 2025

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, announced today it will report earnings results for its fourth quarter fiscal 2025 ended September 30, 2025, on Tuesday, December 16, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, December 16, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676638 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After regi

    12/5/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Announces Appointment of Chief Executive Officer

    Organigram Global Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company's new Chief Executive Officer (CEO). Mr. Yamanaka is expected to assume the role effective on or about January 15, 2026. Mr. Yamanaka will also join the Company's board of directors when he assumes the role of Chief Executive Officer. Mr. Yamanaka is a seasoned executive, having spent more than 20 years at British American Tobacco, with extensive experience in strategy and general management across

    11/25/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Majority of Canadians Want Carney Government to Catch Up on Cannabis Policy

    Three in five Canadians say it's time legal cannabis industry was treated as an economic opportunity Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), Canada's largest cannabis company by market share, today released new national polling figures, conducted on its behalf by Abacus Data showing that a clear majority of Canadians want Ottawa to modernize its approach to the legal cannabis sector. Nearly six in ten Canadians (59%) believe the federal government should do more to support jobs and innovation in the sector, while an equal number (59%) see the legal cannabis industry as an important part of the Canadian economy. "Canadians are ready for the legal cannabis sector to become a pill

    10/29/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity resumed coverage on OrganiGram

    Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

    7/17/24 12:18:49 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OrganiGram upgraded by Alliance Global Partners

    Alliance Global Partners upgraded OrganiGram from Neutral to Buy

    4/15/24 8:40:01 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OrganiGram upgraded by Stifel

    Stifel upgraded OrganiGram from Hold to Buy

    1/13/23 7:36:46 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Leadership Updates

    Live Leadership Updates

    View All

    Organigram Announces Appointment of Chief Executive Officer

    Organigram Global Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company's new Chief Executive Officer (CEO). Mr. Yamanaka is expected to assume the role effective on or about January 15, 2026. Mr. Yamanaka will also join the Company's board of directors when he assumes the role of Chief Executive Officer. Mr. Yamanaka is a seasoned executive, having spent more than 20 years at British American Tobacco, with extensive experience in strategy and general management across

    11/25/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.

    Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on March 24, 2025 (the "Meeting"). Shareholder Approval of the Name Change and Articles of Amendment At the Meeting, a special resolution approving an amendment to the articles of the Company to change the name of the Company to "Organigram Global Inc." (the "Name Change"), was approved by the affirmative vote of 95.778% of the votes represented at the Meeting. The Name Change remains subject to regulatory approvals, including the approval of the TSX. The TSX has conditionally ap

    3/24/25 8:30:00 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Announces Appointment of Craig Harris to Board of Directors

    Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

    7/29/24 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    9/3/24 9:30:26 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    1/25/24 5:23:26 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Financials

    Live finance-specific insights

    View All

    Organigram to Report Fourth Quarter Fiscal 2025 Results on December 16, 2025

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, announced today it will report earnings results for its fourth quarter fiscal 2025 ended September 30, 2025, on Tuesday, December 16, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, December 16, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676638 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After regi

    12/5/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Reports Record Third Quarter Fiscal 2025 Results

    Second consecutive quarter of record revenue, strong adjusted EBITDA growth, Free Cash Flow, and continued international expansion Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its record results for the third quarter ended June 30, 2025 ("Q3 Fiscal 2025" or "Q3"). Q3 FISCAL 2025 HIGHLIGHTS Record Gross Revenue: $110.2 million (+73% year-over-year, +7.2% sequential). Record Net Revenue: $70.8 million (+72% year-over-year, +7.9% sequential). International Revenue: $7.4 million (+208% year-over-year, +21% sequential). Adjusted EBITDA2: $5.7 million (+64% year-over-year, +16%

    8/13/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its third quarter fiscal 2025 ended June 30, 2025, on Wednesday, August 13, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, August 13, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676685 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registe

    8/1/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care